N/A Completed N=45 Treatment

Effect of Whole Body Periodic Acceleration on Airway Endothelial Function

Healthy · Smokers · Asthma

Source: ClinicalTrials.gov NCT01213706 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2014

Primary outcomePrimary: Airway Blood Flow Response to Albuterol — 2.85; -1.43; 17.93; 4.03 μl/min/ml

Summary

In the present proposal the investigators wish to assess the effect of a single session with the device known as Exer-Rest® which applies Whole Body Periodic Acceleration (WBPA) on baseline airway blood flow (Qaw) and in Qaw variation, in current smokers, glucocorticoid-naïve asthmatics, and age-matched healthy never-smokers, with the expectation that the treatment will transiently increase the Qaw, and to a greater extent in the current smokers and patients with asthma who have endothelial dysfunction.

Outcome Measures

Outcome	Result	p-value
PRIMARY Airway Blood Flow Response to Albuterol	2.85; -1.43; 17.93; 4.03; 1.96; 1.65	—

Eligibility Criteria

Inclusion Criteria

15 healthy never-smokers, 15 smokers (> than 1 year smoke history) and 15 never-smokers asthmatics; FEV1 > 80% (except for asthmatics subjets)

Exclusion Criteria

Women of childbearing potential who do not accepted birth control measures; pregnant and breast feeding; cardiovascular disease or use of cardiovascular drugs; respiratory infection during the 4 weeks preceding the study; use of inhaled or systemic glucocorticoids, leukotriene modifiers or theophyllines in asthmatics; FEV1 < 80% on the screening day (excepted for asthmatics subjets)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01213706). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.